Stephen A. Sherwin
Known title: DirectorCIK: 0001079462
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Biogen sees kidney therapy progress and rating upgrade. Biogen is receiving attention after a kidney transplant milestone was reported, highlighting its involvement in kidney disease research. The company’s partner Estuary Therapeutics raised $93 million to advance a gene‑therapy for kidney disease, adding to the pipeline focus. Analysts have upgraded Biogen’s outlook, noting growth potential beyond its Alzheimer’s products. An earnings preview also points to upcoming results that could shape market views.
Transaction History
| NBIX | ▼ Sell | Gift | 1,000 | $0 | 9/2/2026 | View on chart |
| BIIB | ▲ Buy | Grant | 1,505 | $0 | 6/9/2026 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 15,000 | $805K | 6/5/2026 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 10,000 | $798K | 6/5/2026 | View on chart |
| NBIX | ▼ Sell | Open Market | 2,549 | $419K | 6/5/2026 | View on chart |
| NBIX | ▼ Sell | Open Market | 6,896 | $1.1M | 6/5/2026 | View on chart |
| NBIX | ▼ Sell | Open Market | 5,829 | $971K | 6/5/2026 | View on chart |
| NBIX | ▼ Sell | Open Market | 1,843 | $308K | 6/5/2026 | View on chart |
| NBIX | ▼ Sell | Open Market | 7,883 | $1.3M | 6/5/2026 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 3,318 | $0 | 5/21/2026 | View on chart |
| NBIX | ▼ Sell | Gift | 1,000 | $0 | 9/2/2025 | View on chart |
| BIIB | ▲ Buy | Grant | 2,370 | $0 | 6/17/2025 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 2,869 | $0 | 5/22/2025 | View on chart |
| BIIB | ▼ Sell | Open Market | 8,760 | $1.3M | 3/7/2025 | View on chart |
| NBIX | ▼ Sell | Open Market | 13,831 | $1.6M | 2/13/2025 | View on chart |
| NBIX | ▼ Sell | Gift | 2,000 | $0 | 11/4/2024 | View on chart |
| BIIB | ▲ Buy | Grant | 1,340 | $0 | 6/21/2024 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 25,000 | $1.1M | 5/29/2024 | View on chart |
| NBIX | ▼ Sell | Open Market | 25,000 | $3.3M | 5/29/2024 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 15,000 | $718K | 5/29/2024 | View on chart |
| NBIX | ▼ Sell | Open Market | 15,000 | $2.0M | 5/29/2024 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 4,199 | $0 | 5/17/2024 | View on chart |
| NBIX | ▼ Sell | Gift | 2,750 | $0 | 11/16/2023 | View on chart |
| BIIB | ▲ Buy | Grant | 960 | $0 | 6/26/2023 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 15,000 | $191K | 1/3/2023 | View on chart |
| NBIX | ▼ Sell | Open Market | 15,000 | $1.8M | 1/3/2023 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 15,000 | $195K | 1/3/2023 | View on chart |
| NBIX | ▼ Sell | Open Market | 15,000 | $1.8M | 1/3/2023 | View on chart |
| BIIB | ▲ Buy | Grant | 1,370 | $0 | 6/15/2022 | View on chart |
| NBIX | ▲ Buy | Option Exercise | 15,000 | $100K | 1/24/2022 | View on chart |
| NBIX | ▼ Sell | Open Market | 15,000 | $1.1M | 1/24/2022 | View on chart |
| NBIX | ▼ Sell | Gift | 2,000 | $0 | 12/14/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
NBIX Faces Mixed Analyst Views Amid CAH Data Presentation
Neurocrine Biosciences is presenting real-world data on congenital adrenal hyperplasia at an upcoming medical symposium. While Needham reiterated a positive stance with a $204 target, BMO Capital lowered its target to $150, reflecting a wide range of analyst expectations. The stock is currently trading near its support level, with the average analyst target remaining well above the current price.
NBIX Faces Mixed Analyst Views Amid CAH Data Presentation. Neurocrine Biosciences is presenting real-world data on congenital adrenal hyperplasia at an upcoming medical symposium. While Needham reiterated a positive stance with a $204 target, BMO Capital lowered its target to $150, reflecting a wide range of analyst expectations. The stock is currently trading near its support level, with the average analyst target remaining well above the current price.